ID

14838

Descripción

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00176774

Link

https://clinicaltrials.gov/show/NCT00176774

Palabras clave

Versiones (1)
  1. 1/5/16 1/5/16 -
Subido en

1 de mayo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Colorectal Carcinoma NCT00176774

Inglés

Eligibility Colorectal Carcinoma NCT00176774

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis.
Descripción

ID.1

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0001418
UMLS CUI [1,2]
C0034896
UMLS CUI [1,3]
C0001418
UMLS CUI [1,4]
C0009368
UMLS CUI [1,5]
C0019638
UMLS CUI [2]
C0027627
patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. patients must not have been previously treated with the combination of irinotecan/5-fu/lv.
Descripción

ID.2

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2,1]
C0123931
UMLS CUI [2,2]
C0016360
UMLS CUI [2,3]
C0023413
patients must be past their 18th birthday at the time of enrollment.
Descripción

ID.3

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patients must have a performance status of 0-2 at the time of registration.
Descripción

ID.4

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
patients must have a life expectancy of > 3 months.
Descripción

ID.5

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
if patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment.
Descripción

ID.6

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2004454
patients must have a pretreatment leukocyte count > 3,000/l, absolute neutrophil count >1500/l, hemoglobin >8 mg/dl, and platelet count of > 150,000/l within 2 weeks of enrollment.
Descripción

ID.7

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0518015
UMLS CUI [4]
C0032181
patients must have adequate renal function, as documented by a serum creatinine < 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin < 1.1 mg/dl within 2 weeks of enrollment.
Descripción

ID.8

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0201976
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients must not have active infection.
Descripción

ID.9

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent.
Descripción

ID.10

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment.
Descripción

ID.11

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
pregnant or lactating women may not participate. women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. men and women of reproductive potential must use an effective contraceptive method during the study.
Descripción

ID.12

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0015895
UMLS CUI [4]
C0700589
there must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol.
Descripción

ID.13

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1707479
all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
Descripción

ID.14

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Volver a la parte superior de la página

Similar models

Eligibility Colorectal Carcinoma NCT00176774

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis.
boolean
C0001418 (UMLS CUI [1,1])
C0034896 (UMLS CUI [1,2])
C0001418 (UMLS CUI [1,3])
C0009368 (UMLS CUI [1,4])
C0019638 (UMLS CUI [1,5])
C0027627 (UMLS CUI [2])
ID.2
Item
patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. patients must not have been previously treated with the combination of irinotecan/5-fu/lv.
boolean
C0392920 (UMLS CUI [1])
C0123931 (UMLS CUI [2,1])
C0016360 (UMLS CUI [2,2])
C0023413 (UMLS CUI [2,3])
ID.3
Item
patients must be past their 18th birthday at the time of enrollment.
boolean
C0001779 (UMLS CUI [1])
ID.4
Item
patients must have a performance status of 0-2 at the time of registration.
boolean
C1520224 (UMLS CUI [1])
ID.5
Item
patients must have a life expectancy of > 3 months.
boolean
C0023671 (UMLS CUI [1])
ID.6
Item
if patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment.
boolean
C2004454 (UMLS CUI [1])
ID.7
Item
patients must have a pretreatment leukocyte count > 3,000/l, absolute neutrophil count >1500/l, hemoglobin >8 mg/dl, and platelet count of > 150,000/l within 2 weeks of enrollment.
boolean
C0023508 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
ID.8
Item
patients must have adequate renal function, as documented by a serum creatinine < 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin < 1.1 mg/dl within 2 weeks of enrollment.
boolean
C1278039 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
ID.9
Item
patients must not have active infection.
boolean
C0009450 (UMLS CUI [1])
ID.10
Item
patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent.
boolean
C0009488 (UMLS CUI [1])
ID.11
Item
patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment.
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
ID.12
Item
pregnant or lactating women may not participate. women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. men and women of reproductive potential must use an effective contraceptive method during the study.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0015895 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
ID.13
Item
there must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol.
boolean
C1707479 (UMLS CUI [1])
ID.14
Item
all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
boolean
C0021430 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial